Nathalie Vernaz

Nathalie Vernaz

Auto-generated profile, based on publicly available information

Nathalie Vernaz

Affiliation Medical Directorate, Finance Directorate, Geneva University Hospitals, Geneva University, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2008 in JAMA
Verified
Journal Article
Open access
PDF file
SHStephan Harbarth
Stephan Harbarth
CFCarolina Fankhauser
Carolina Fankhauser
JSJacques Schrenzel
Jacques Schrenzel
JCJan Christenson
Jan Christenson
PGPascal Gervaz
Pascal Gervaz
DPDidier Pittet
Didier Pittet
Carriage of antimicrobial-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) places patients at high risk of infection.1,2 Early identification of patients colonized with MRSA and subsequent prevention of patient-to-patient spread through infection control measures are believed to be potent interventions to control MRSA.3 In addition, rapid MRSA screening of surgical patients may decrease MRSA infections by facilitating appropriate selection of antibiotic agents for preoperative prophylaxis.4

15 June 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ALAndie S. Lee
Andie S. Lee
Marina Macedo-ViñasMarina Macedo-Viñas
Marina Macedo-Viñas
PFPatrice François
Patrice François
GRGesuele Renzi
Gesuele Renzi
JSJacques Schrenzel
Jacques Schrenzel
SHStephan Harbarth
Stephan Harbarth
Background. The clinical importance of low-level mupirocin resistance and genotypic chlorhexidine resistance remains unclear. We aimed to determine whether resistance to these agents increases the risk of persistent methicillin-resistant Staphylococcus aureus (MRSA) carriage after their use for topical decolonization therapy. Methods. A nested case-control study was conducted of MRSA carriers who received decolonization therapy from 2001 through 2008. Cases, patients who remained colonized, were matched by year to controls, those in whom MRSA was eradicated (follow-up, 2 years). Baseline MRSA isolates were tested for mupirocin resistance by Etest and chlorhexidine resistance by qacA/B polymerase chain reaction. MRSA carriers with high-level mupirocin resistance were excluded. The effect of the primary exposure of interest, low-level mupirocin and genotypic chlorhexidine resistance, was evaluated with multivariate conditional logistic regression analysis. Results. The 75 case patients and 75 control patients were similar except that those persistently colonized were older (P = .007) with longer lengths of hospital stay (P = .001). After multivariate analysis, carriage of combined low-level mupirocin and genotypic chlorhexidine resistance before decolonization independently predicted persistent MRSA carriage (odds ratio [OR], 3.4 [95% confidence interval {CI}, 1.5–7.8]). Other risk factors were older age (OR, 1.04 [95% CI, 1.02–1.1]), previous hospitalization (OR, 2.4 [95% CI, 1.1–5.7]), presence of a skin wound (OR, 5.7 [95% CI, 1.8–17.6]), recent antibiotic use (OR, 3.1 [95% CI, 1.3–7.2]), and central venous catheterization (OR, 5.7 [95% CI, 1.4–23.9]). Conclusions. Combined low-level mupirocin and genotypic chlorhexidine resistance significantly increases the risk of persistent MRSA carriage after decolonization therapy. Institutions with widespread use of these agents should monitor for resistance and loss of clinical effectiveness.

8 May 2008 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NVNathalie Vernaz
Nathalie Vernaz
HSHugo Sax
Hugo Sax
DPDidier Pittet
Didier Pittet
PBPascal Bonnabry
Pascal Bonnabry
JSJacques Schrenzel
Jacques Schrenzel
SHStephan Harbarth
Stephan Harbarth
The aim of this study was to determine the temporal relation between the use of antibiotics and alcohol-based hand rubs (ABHRs) and the incidence of methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. An interventional time-series analysis was performed to evaluate the impact of two promotion campaigns on the consumption of ABHRs and to assess their effect on the incidence of non-duplicate clinical isolates of MRSA and C. difficile from February 2000 through September 2006. This analysis was combined with a transfer function model of aggregated data on antibiotic use. Consumption of ABHRs correlated with MRSA, but not with C. difficile. The final model demonstrated the immediate effect of the second hand hygiene promotion campaign and an additional temporal effect of fluoroquinolone (time lag, 1 month; i.e. antibiotic effect delayed for 1 month), macrolide (lag 1 and 4 months), broad-spectrum cephalosporins (lag 3, 4 and 5 months) and piperacillin/tazobactam (lag 3 months) use. The final model explained 57% of the MRSA variance over time. In contrast, the model for C. difficile showed only an effect for broad-spectrum cephalosporins (lag 1 month). We observed an aggregate-level relation between the monthly MRSA incidence and the use of different antibiotic classes and increased consumption of ABHR after a successful hand hygiene campaign, while no association with ABHR use was detected for C. difficile.

9 December 2011 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MAMamoon Aldeyab
Mamoon Aldeyab
SHStephan Harbarth
Stephan Harbarth
NVNathalie Vernaz
Nathalie Vernaz
MKMary P. Kearney
Mary P. Kearney
Michael ScottMichael Scott
Michael Scott
JMJames C. McElnay
James C. McElnay
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The emergence and spread of bacteria producing extended‐spectrum beta‐lactamases (ESBLs) has important therapeutic and epidemiologic implications.• A key target for the establishment of hospital antibiotic stewardship is reducing the occurrence of additional antibiotic resistance.• Further research is needed to accumulate supporting evidence that reducing antibiotic use will result in a parallel reduction in antibiotic resistance.WHAT THIS STUDY ADDS• Fluoroquinolone restriction reversed ciprofloxacin resistance in primary and secondary healthcare settings.• Fluoroquinolone restriction reduced ESBL‐producing bacteria incidence rates in both the primary and secondary healthcare settings.• This study highlights the value of time‐series analysis in designing efficient antibiotic stewardship.AIMS: The objective of the present study was to study the relationship between hospital antibiotic use, community antibiotic use and the incidence of extended‐spectrum beta‐lactamase (ESBL)‐producing bacteria in hospitals, while assessing the impact of a fluoroquinolone restriction policy on ESBL‐producing bacteria incidence rates.METHODS: The study was retrospective and ecological in design. A multivariate autoregressive integrated moving average (ARIMA) model was built to relate antibiotic use to ESB‐producing bacteria incidence rates and resistance patterns over a 5 year period (January 2005–December 2009).RESULTS: Analysis showed that the hospital incidence of ESBLs had a positive relationship with the use of fluoroquinolones in the hospital (coefficient = 0.174, P= 0.02), amoxicillin‐clavulanic acid in the community (coefficient = 1.03, P= 0.03) and mean co‐morbidity scores for hospitalized patients (coefficient = 2.15, P= 0.03) with various time lags. The fluoroquinolone restriction policy was implemented successfully with the mean use of fluoroquinolones (mainly ciprofloxacin) being reduced from 133 to 17 defined daily doses (DDDs)/1000 bed days (P < 0.001) and from 0.65 to 0.54 DDDs/1000 inhabitants/day (P= 0.0007), in both the hospital and its surrounding community, respectively. This was associated with an improved ciprofloxacin susceptibility in both settings [ciprofloxacin susceptibility being improved from 16% to 28% in the community (P < 0.001)] and with a statistically significant reduction in ESBL‐producing bacteria incidence rates.DISCUSSION: This study supports the value of restricting the use of certain antimicrobial classes to control ESBL, and demonstrates the feasibility of reversing resistance patterns post successful antibiotic restriction. The study also highlights the potential value of the time‐series analysis in designing efficient antibiotic stewardship.

19 January 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NVNathalie Vernaz
Nathalie Vernaz
BHBenedikt D. Huttner
Benedikt D. Huttner
DMDaniel Muscionico
Daniel Muscionico
JSJean-Luc Salomon
Jean-Luc Salomon
PBPascal Bonnabry
Pascal Bonnabry
SHStephan Harbarth
Stephan Harbarth
To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant Escherichia coli in both the inpatient and outpatient setting of a large urban area. A retrospective observational time-series analysis was performed to evaluate the incidence of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from January 2000 through December 2007, combined with a transfer function model of aggregated data on antibiotic use in both settings obtained from the hospital's pharmacy and outpatient billing offices. Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P  < 0.0001) and cefepime resistance from 0.9% (2002) to 3.2% (2007; P= 0.01). Trimethoprim/sulfamethoxazole resistance remained stable (23.7%–25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased significantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli isolates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag 4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in E. coli was correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in the hospital (R2  = 51%). These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli including extended-spectrum β-lactamase producers and show the added value of time-series analysis to better understand the interaction between community and hospital antibiotic prescribing and its spill-over effect on antibiotic resistance.

1 March 2016 in Science of The Total Environment
Verified
Journal Article
Closed access
SDSilwan Daouk
Silwan Daouk
NCNathalie Chèvre
Nathalie Chèvre
NVNathalie Vernaz
Nathalie Vernaz
CWChristèle Widmer
Christèle Widmer
Daali YoussefDaali Youssef
Daali Youssef
SFSandrine Fleury-Souverain
Sandrine Fleury-Souverain